ENDO 2016:甲状腺功能减退可能增加糖尿病风险

2016-04-05 Mechront 译 MedSci原创

内分泌学会年会上称,即使是轻度甲状腺功能减退,也会增加2型糖尿病风险。荷兰鹿特丹港市伊拉斯莫斯医学中心的Layal Chaker博士说:“甲状腺功能低于下限或是在正常范围下限,都会增加2型糖尿病风险,或是加速前驱糖尿病发展为2型糖尿病的进展。”她说:“前驱糖尿病患者发展为糖尿病的风险在正常甲功上限时为19%,而下限时则为35%。”这项基于人群的前瞻性队列研究,Chaker和同事对8452名≥45岁

内分泌学会年会上称,即使是轻度甲状腺功能减退,也会增加2型糖尿病风险。

荷兰鹿特丹港市伊拉斯莫斯医学中心的Layal Chaker博士说:“甲状腺功能低于下限或是在正常范围下限,都会增加2型糖尿病风险,或是加速前驱糖尿病发展为2型糖尿病的进展。”

她说:“前驱糖尿病患者发展为糖尿病的风险在正常甲功上限时为19%,而下限时则为35%。”

这项基于人群的前瞻性队列研究,Chaker和同事对8452名≥45岁的成年人进行了一样研究,参与者平均年龄65岁,研究人员获取了甲功和血糖等数据,平均随访7.9年。

随访期间有1100名参与者发展为前驱糖尿病,798名发展为糖尿病。校正基线年龄、性别、HDL胆固醇、血压和血糖等因素后,更高的促甲状腺激素(TSH)与更高的糖尿病风险相关(HR = 1.13; 95% CI, 1.08-1.18, per logTSH),更高的游离甲状腺素水平与更低的糖尿病风险相关(HR = 0.96, CI, 0.93-0.99, per pmol/L)。就算在正常范围内,这种联系也存在(TSH, HR = 1.24; 95% CI, 1.06-1.45; 游离 T4, HR = 0.96; 95% CI, 0.93-0.99, per pmol/L)。正常范围内甲功最高值组与最低值组相比,前驱糖尿病进展为糖尿病的风险为1.4倍(P = .002)。

Chaker说:“我们的结果表明,甲状腺激素在2型糖尿病的病理发展机制中有一定作用。不过我们还需要进一步了解和认识甲状腺激素与糖尿病的关系。”

原始出处:

Chaker L, et al. OR22-1. Presented at: The Endocrine Society Annual Meeting; April 1-4, 2016; Boston.

Low thyroid function linked to type 2 diabetes.Healio.April 3, 2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=79283, encodeId=548be928326, content=涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cc71713672, createdName=hewenda, createdTime=Sun Apr 17 23:50:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78404, encodeId=7a9fe840402, content=跟踪学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9cca1435077, createdName=sunshineliyi, createdTime=Thu Apr 14 22:13:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76045, encodeId=60ece604575, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Apr 06 15:46:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75775, encodeId=28bbe5775af, content=学习了又一疾病间关联, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Wed Apr 06 09:19:00 CST 2016, time=2016-04-06, status=1, ipAttribution=)]
    2016-04-17 hewenda

    涨知识了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=79283, encodeId=548be928326, content=涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cc71713672, createdName=hewenda, createdTime=Sun Apr 17 23:50:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78404, encodeId=7a9fe840402, content=跟踪学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9cca1435077, createdName=sunshineliyi, createdTime=Thu Apr 14 22:13:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76045, encodeId=60ece604575, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Apr 06 15:46:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75775, encodeId=28bbe5775af, content=学习了又一疾病间关联, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Wed Apr 06 09:19:00 CST 2016, time=2016-04-06, status=1, ipAttribution=)]
    2016-04-14 sunshineliyi

    跟踪学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=79283, encodeId=548be928326, content=涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cc71713672, createdName=hewenda, createdTime=Sun Apr 17 23:50:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78404, encodeId=7a9fe840402, content=跟踪学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9cca1435077, createdName=sunshineliyi, createdTime=Thu Apr 14 22:13:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76045, encodeId=60ece604575, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Apr 06 15:46:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75775, encodeId=28bbe5775af, content=学习了又一疾病间关联, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Wed Apr 06 09:19:00 CST 2016, time=2016-04-06, status=1, ipAttribution=)]
    2016-04-06 dhzzm

    学习了,很好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=79283, encodeId=548be928326, content=涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cc71713672, createdName=hewenda, createdTime=Sun Apr 17 23:50:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78404, encodeId=7a9fe840402, content=跟踪学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9cca1435077, createdName=sunshineliyi, createdTime=Thu Apr 14 22:13:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76045, encodeId=60ece604575, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Apr 06 15:46:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75775, encodeId=28bbe5775af, content=学习了又一疾病间关联, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Wed Apr 06 09:19:00 CST 2016, time=2016-04-06, status=1, ipAttribution=)]
    2016-04-06 yilibaisha

    学习了又一疾病间关联

    0

相关资讯

Int J Endocrinol:甲状腺功能看什么指标?

  Int J Endocrinol:甲状腺功能看什么指标? 评价患者的甲状腺功能看什么指标好,上海同济大学医学院的研究者们将为你解答甲状腺功能最有价值的指标,或许对你的临床实践有帮助。 研究背景及目的:甲状腺功能的正常对于维持人体正常代谢、生长发育、内环境的稳定有重要作用,血清促甲状腺激素(TSH)被认为是评价甲状腺功能最有价值的指标,FT3、FT4在血液中是起生物学作

Nat rev2011内分泌研究进展:妊娠期甲状腺疾病

文献标题:Thyroid disease in pregnancy in 2011: Thyroid function--effects on mother and baby unraveled.(全文) 期刊来源:Nature reviews. Endocrinology.2012-02;8(2):69-70. 期刊影响因子:9.191 妊娠期甲状腺疾病2011:甲状腺功能对母亲

BMJ:亚临床甲状腺病房颤风险升高

  丹麦学者的一项研究表明,新发房颤风险随甲状腺功能而变化,并且在亚临床甲状腺疾病中显著升高,如不伴正常高值游离甲状腺素的促甲状腺激素(TSH)水平降低。论文于2012年11月27日在线发表于《英国医学杂志》(BMJ)。   此项基于人群的队列研究共纳入586460例受试者(平均年龄50.2岁,男性39%)。受试者均接受甲状腺功能评估,并且既往无甲状腺疾病或房颤。利用Poisson回归模型估算依